AnGes, Inc. Logo

AnGes, Inc.

Biopharmaceutical firm developing gene-based and nucleotide-based medicines.

4563 | T

Overview

Corporate Details

ISIN(s):
JP3127700007
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号

Description

AnGes, Inc. is a biopharmaceutical company specializing in the research and development of gene-based and nucleotide-based medicines. The company's core focus is its Hepatocyte Growth Factor (HGF) gene therapy product, designed to treat ischemic diseases by regenerating blood vessels. This product was the first gene therapy medicine to receive marketing approval in Japan. AnGes leverages its expertise in plasmid DNA technology across its development pipeline, which also includes an NFkB decoy oligonucleotide and DNA vaccines. The company is dedicated to developing novel treatments for various conditions, including rare diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-08-12 02:09
確認書
Japanese 8.9 KB
2022-08-12 02:08
四半期報告書-第24期第2四半期(令和4年4月1日-令和4年6月30日)
Japanese 495.7 KB
2022-05-13 02:13
四半期報告書-第24期第1四半期(令和4年1月1日-令和4年3月31日)
Japanese 366.6 KB
2022-03-31 03:10
内部統制報告書-第23期(令和3年1月1日-令和3年12月31日)
Japanese 23.7 KB
2022-03-31 03:09
有価証券報告書-第23期(令和3年1月1日-令和3年12月31日)
Japanese 1.4 MB
2022-03-31 03:09
確認書
Japanese 9.0 KB
2021-11-12 02:11
四半期報告書-第23期第3四半期(令和3年7月1日-令和3年9月30日)
Japanese 373.8 KB
2021-08-13 02:31
四半期報告書-第23期第2四半期(令和3年4月1日-令和3年6月30日)
Japanese 416.5 KB
2021-05-14 02:20
四半期報告書-第23期第1四半期(令和3年1月1日-令和3年3月31日)
Japanese 444.1 KB
2021-03-31 02:43
内部統制報告書-第22期(令和2年1月1日-令和2年12月31日)
Japanese 23.8 KB
2021-03-31 02:40
確認書
Japanese 9.0 KB
2021-03-31 02:38
有価証券報告書-第22期(令和2年1月1日-令和2年12月31日)
Japanese 1.7 MB
2020-11-12 01:25
四半期報告書-第22期第3四半期(令和2年7月1日-令和2年9月30日)
Japanese 393.1 KB
2020-08-12 03:07
四半期報告書-第22期第2四半期(令和2年4月1日-令和2年6月30日)
Japanese 397.7 KB
2020-05-13 02:08
四半期報告書-第22期第1四半期(令和2年1月1日-令和2年3月31日)
Japanese 390.5 KB

Automate Your Workflow. Get a real-time feed of all AnGes, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AnGes, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AnGes, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.